Phase 2 Trial of Neuren’s NNZ-2591 Cleared to Start in US, Australia
Neuren has received the green light from regulators in the U.S. and Australia to conduct its Phase 2 trial of NNZ-2591 for Angelman syndrome.
0 Comments
Phase 2 Trial of Neuren’s NNZ-2591 Cleared to Start in US, Australia
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed